|
||||||||||||||||||||
(MURD= matched unrelated donor, MRD= matched related donor, nd= not done, DFS= disease free survival, OS= overall survival, GVHD= graft-versus-host disease) *in the case of CCR5-delta32 for both donor and recipient, respectively **not significant | ||||||||||||||||||||
Table 2: Summary of studies focusing on the outcome of allogeneic hematopoietic stem cell transplantation in regard to different CCR5 polymorphism. |